People

Found 61,765 articles

• Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

  1/4/2024

  Innate Pharma SA announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.

• Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

  1/3/2024

  Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, is pleased to announce the appointment of Dr. Brian Alvin Johns, Ph.D., as Chief Scientific Officer, effective January 3, 2024.

• Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO

  1/3/2024

  Radionetics Oncology, Inc. announces the completion of a $52.5 million Series A financing.

• ProMIS Neurosciences, Inc. Announces Leadership Transition

  1/3/2024

  ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced a strategic leadership change.

• Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock

  1/3/2024

  Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”), offered at a price of $28.50 per share, before underwriting discounts.

• NuView Life Sciences Announces the Appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to Board of Directors

  1/3/2024

  NuView Life Sciences, Inc. announced the appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to its board of directors.

• Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer

  1/3/2024

  Switch Therapeutics today announced the appointment of Charles Allerson, Ph.D.

• InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

  1/3/2024

  InspireMD announced the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America.

• Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer

  1/3/2024

  Star Therapeutics today announced the appointment of Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer.

• VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

  1/3/2024

  VYNE Therapeutics Inc. today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024.

• Medytox, Inc. Announces the Formation of Luvantas Subsidiary and Appointment of Key Executives

  1/3/2024

  Medytox, Inc. is pleased to announce the formation of Luvantas, Inc. as its wholly-owned North American subsidiary.

• Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial OfficerDr. Vendola Brings Deep, Hands-On Industry Strategy, Operational and Financial Expertise to the Role

  1/3/2024

  Wugen, Inc. announced the appointment of Keith Vendola, M.D., M.B.A., as chief financial officer, effective October 2023.

• Curtis A. Cluff Named Chief Executive Officer of BioPhotas, Inc.

  1/3/2024

  BioPhotas, Inc., the market leader in therapeutic LED Light Therapy devices announced that its Board of Directors has named Curtis A. Cluff as the Company's CEO.

• Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor

  1/3/2024

  Arrivo BioVentures proudly announces the appointment of Dr. Joel Raskin as its Chief Medical Advisor.

• Assertio Holdings, Inc. Announces Leadership Transition

  1/3/2024

  Assertio Holdings, Inc., a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced that Dan Peisert is stepping down as the Company’s Chief Executive Officer.

• ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

  1/3/2024

  ReAlta Life Sciences, Inc., a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately.

• Foghorn Therapeutics Announces CFO Departure - Jan 03, 2024

  1/3/2024

  Foghorn® Therapeutics Inc. announced that Chief Financial Officer, Allan Reine will be departing the Company to pursue another opportunity.

• Synchron Appoints Riki Banerjee as Chief Technology Officer

  1/3/2024

  Synchron today announced the appointment of Riki Banerjee, Ph.D., to Chief Technology Officer (CTO).

• Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth

  1/3/2024

  Simulations Plus, Inc. announced the following leadership changes effective January 3, 2024.

• NYU Grossman School of Medicine and Sarah Lawrence College Launch Graduate Genomics Degree Program

  1/3/2024

  NYU Grossman School of Medicine's Vilcek Institute of Graduate Biomedical Sciences and Sarah Lawrence College announced the launch of a master's program in genome health analysis.